Codexis, Inc. (FRA:4QK)

Market Cap	127.96M
Revenue (ttm)	45.11M
Net Income (ttm)	-54.51M
Shares Out	n/a
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	95
Open	1.377
Previous Close	1.386
Day's Range	1.376 - 1.438
52-Week Range	1.319 - 5.240
Beta	n/a
RSI	44.68
Earnings Date	Feb 27, 2026

About Codexis

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorp...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 188
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4QK

Financial Performance

In 2024, Codexis's revenue was $59.35 million, a decrease of -15.39% compared to the previous year's $70.14 million. Losses were -$65.28 million, -14.38% less than in 2023.

Financial numbers in USD